

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)



(10) International Publication Number
WO 2023/159040 A1

(51) International Patent Classification:

A61K 31/473 (2006.01) *A61K 9/28* (2006.01)
A61K 45/06 (2006.01) *A61K 9/48* (2006.01)
A61K 31/33 (2006.01) *A61K 9/14* (2006.01)

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/062621

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

15 February 2023 (15.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/268,017 15 February 2022 (15.02.2022) US

(71) Applicant: **FORESEE PHARMACEUTICALS CO., LTD.**; 9f-2., No. 19-3, Sanchong Rd., Nangang Dist., Taipei City, 115 (TW).

(72) Inventor; and

(71) Applicant: **LI, Yuhua** [US/US]; c/o Foresee Pharmaceuticals Usa, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US).

(72) Inventors: **JANG, Shih-fan**; c/o Foresee Pharmaceuticals Co., Ltd., 9f-2., No. 19-3, Sanchong Rd., Nangang Dist., Taipei City, 115 (TW). **HUANG, Wen-yen**; c/o Foresee Pharmaceuticals Co., Ltd., 9f-2., No. 19-3, Sanchong Rd., Nangang Dist., Taipei City, 115 (TW). **LI, Ming-hsin**; C/o Foresee Pharmaceuticals Co., Ltd., 9f-2., No. 19-3, Sanchong Rd., Nangang Dist., Taipei City, 115 (TW).

(74) Agent: **HE, Ming** et al.; Ice Miller LLP, 1735 Market Street, Suite 3900, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

(54) Title: CRYSTALLINE (+)-TETRABENAZINE

(57) Abstract: The present application relates to crystal forms of (+)-tetrabenazine. The present application also relates to a pharmaceutical composition comprising the crystal form of (+)-tetrabenazine, as well as methods of using the crystal forms of (+)-tetrabenazine in the treatment of hyperkinetic movement disorders, and methods for obtaining such crystal forms.

WO 2023/159040 A1